Acute Myeloid Leukemia Market size was valued at USD 3.41 billion in 2024 and is likely to cross USD 12.63 billion by 2037, expanding at more than 10.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of acute myeloid leukemia is assessed at USD 3.7 billion.
The number of acute myeloid leukemia patients is rising owing to the aging population across the globe. Like many other malignancies, acute myeloid leukemia (AML) is a hematological neoplasm that typically affects the elderly, with a median age of presentation of 67 years.
According to the World Health Organization (WHO), the number of individuals 60 years of age and over will double (to 2.1 billion) worldwide by 2050.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
10.6% |
|
Base Year Market Size |
USD 3.41 billion |
|
Forecast Year Market Size |
USD 12.63 billion |
|
Regional Scope |
|
Treatment Type [Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy), Targeted Therapy, Immunotherapy, Hormone Therapy]
Chemotherapy segment is estimated to capture over 62% acute myeloid leukemia market share by 2037. Chemotherapy is significantly utilized for the solidification treatment of acute myeloid leukemia. Owing to its effectiveness in curing AML the cytarabine is massively utilized during chemotherapy.
According to organizations working in the field of cancer, cytarabine a type of chemotherapy drug is more efficient at treating acute myeloid leukemia and that's why it gets so much use.
The growth of this market is also expected to be driven by an increase in US Food and Drug Administration approval for cytarabine as a treatment for acute myelodysplastic syndrome.
For instance, in March 2021 Jazz Pharmaceuticals plc announced that it received approval from the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos (daunorubicin and cytarabine) to add a new indication for the treatment of children patients one year of age and older with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related alterations to advance cancer research and concentrating on the individuals who can benefit from it most.
End Users (Hospitals, Homecare, Specialty Centers)
Hospital segment in the acute myeloid leukemia market is poised to grow at over 10% CAGR between 2024 and 2037. The growth can be accredited to the growing healthcare industry. Several countries across the globe are investing in the development of healthcare infrastructure, leading to improvement in cancer treatment, and diagnostic facilities through earlier detection and treatment of acute myeloid leukemia disease.
More and more hospitals around the world are being equipped with advanced facilities to provide AML patients with integrated care. In addition, screening, and treatment facilities are provided to the patients under one roof in hospitals.
For instance, by 2026, it is anticipated that the healthcare sector in India will generate more than USD 600 billion.
Disease Type (Myeloblastic, Promyelocytic, Myelomonocytic)
Myeloblastic segment is expected to dominate over 40% acute myeloid leukemia market share by 2037. This growth of the segment is set to be encouraged by the growing pediatric population. Acute myeloblastic leukemia, the second most common type of leukemia in children, is a malignant disorder where the bone marrow creates an enormous amount of abnormal blood cells and has the worst prognosis of all childhood cancers.
According to estimates, more than 20% of people on the planet are under the age of 15.
Our in-depth analysis of the market includes the following segments:
|
Disease Type |
|
|
Treatment Type |
|
|
Route of Administration |
|
|
End Users |
|
|
Distribution Channel |
|
|
Regimen |
|
North American Market Forecasts
North America in acute myeloid leukemia market is estimated to hold over 40% revenue share by the end of 2037. The growth of this market in the region will be impelled by the growing R&D and product launches. This has led to the discovery of more effective therapies in the field of acute myeloid leukemia.
Besides this, the increasing incidence of acute myeloid leukemia in the United States is likely to drive market expansion. For instance, there were 60,650 new instances of leukemia cancer in the US in 2022, with 24,000 of those cases projected to result in death.
Canada has progressively increased AML incidence rates, with an estimated average of 30.61 cases per million people per year.
APAC Market Statistics
The Asia Pacific acute myeloid leukemia market is set to grow significantly during the period between 2024-2037. There is an increasing prevalence of AML in the region on account of population growth. As a result, there is a growing acceptability of novel treatments and therapies leading to more people obtaining timely therapy.
As per UNFPA, approximately 4.3 billion people, or 60% of the world's population, live in the Asia and Pacific area.
China is home to one in five children worldwide who suffer from acute lymphoblastic leukemia, and more than 55% of the 75.3 thousand new cases of leukemia in China each year are AML patients.
The majority of adult leukemia cases in Korea are caused by acute myeloid leukemia (AML), a representative blood malignancy, which has been a significant national public health concern.
Substantial progress has been made recently in the identification and management of AML in Japan, leading to the generation of a need for novel and more potent AML treatments. AML and other diseases such as multiple myeloma are key areas of attention for the Japanese government, which is constantly trying to improve access to current medications while also sponsoring research into novel AML treatments.
The acute myeloid leukemia market consists of several key players who are launching various strategic initiatives to expand their market position in the acute myeloid leukemia industry.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?